Genelux Corp (GNLX) competitors & alternatives
Health Care · NASDAQ
Genelux Corp (GNLX)'s top competitors and alternatives — its most similar public companies — include REPLIMUNE GROUP INC (REPL), Summit Therapeutics (SMMT), CANDEL THERAPEUTICS INC (CADL), IMMUNITYBIO INC (IBRX), ARRIVENT BIOPHARMA INC (AVBP), IOVANCE BIOTHERAPEUTICS INC (IOVA), BridgeBio Oncology Therapeutics, Inc. (BBOT), BLACK DIAMOND THERAPEUTICS INC (BDTX), Bristol Myers Squibb (BMY), NEKTAR THERAPEUTICS (NKTR), VIR BIOTECHNOLOGY INC (VIR) and LYELL IMMUNOPHARMA INC (LYEL). These are Genelux Corp's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top GNLX competitors & alternatives
-
REPLIMUNE GROUP INCREPLHealth Care
Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in…
$10.75 (as of 2026-07-22) · market cap $918M
-
Summit TherapeuticsSMMTHealth Care
Oncology-focused biotech developing ivonescimab, a first-in-class bispecific antibody combining PD-1 immunotherapy with anti-VEGF anti-angiogenesis, with Phase…
$14.74 (as of 2026-07-22) · market cap $11.4B
-
CANDEL THERAPEUTICS INCCADLHealth Care
Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic…
$10.09 (as of 2026-07-22) · market cap $739M
-
IMMUNITYBIO INCIBRXHealth Care
ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to…
$7.51 (as of 2026-07-22) · market cap $8.0B
-
ARRIVENT BIOPHARMA INCAVBPHealth Care
Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung…
$30.44 (as of 2026-07-22) · market cap $1.3B
-
IOVANCE BIOTHERAPEUTICS INCIOVAHealth Care
Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma…
$5.17 (as of 2026-07-22) · market cap $2.3B
-
BridgeBio Oncology Therapeutics, Inc.BBOTHealth Care
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including…
$8.90 (as of 2026-07-22) · market cap $701M
-
BLACK DIAMOND THERAPEUTICS INCBDTXHealth Care
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey inhibitors designed to target families of oncogenic mutations across…
$1.83 (as of 2026-07-22) · market cap $106M
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
NEKTAR THERAPEUTICSNKTRHealth Care
A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
$69.32 (as of 2026-07-22) · market cap $2.4B
-
VIR BIOTECHNOLOGY INCVIRHealth Care
Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking…
$9.35 (as of 2026-07-22) · market cap $1.6B
-
LYELL IMMUNOPHARMA INCLYELHealth Care
Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a…
$12.84 (as of 2026-07-22) · market cap $315M
Not quite? Describe exactly what you want →
Peers are Genelux Corp's closest public companies by shared sub-industry, sector and business themes. See the full profile: Genelux Corp (GNLX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.